Navigation Links
Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010
Date:4/29/2009

ation on employee stock plans 35.5 29.4 Tax benefit on employee stock plans 30.5 40.9 Excess tax benefits from stock-based compensation arrangements (11.6) (24.2) Other 33.5 33.8 Net changes in assets and liabilities: Manufacturer accounts receivable, net (107.4) (176.2) Client accounts receivable, net 0.9 (125.8) Inventories, net 180.6 (21.0) Prepaid expenses and other current assets 254.3 (5.8) Income taxes receivable (1.3) 7.9 Other noncurrent assets 2.6 (4.0) Claims and other accounts payable (88.3) (365.4) Client rebates and guarantees payable 413.1 389.7 Accrued expenses and other current and noncurrent liabilities 58.3 48.8 ---- ---- Net cash provided by operating activities 1,170.3 165.5 ------- ----- Cash flows from investing activities: Capital expenditures (35.4) (39.1) Purchases of securities and other assets (105.6) (6.5) Proceeds from sale of securities and other investments 44.1 - ----- ----- Net cash used by investing activities (96.9) (45.6) ----- ----- Cash flows from financing activities: Proceeds from long-term debt - 1,885.7 Repayments
'/>"/>
SOURCE Medco Health Solutions, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

Related biology technology :

1. Medco CEO to Shareholders: Delivering Results, Driving Shareholder Value
2. Medco to Present at the Deutsche Bank 33rd Annual Health Care Conference
3. Medco Issues $1.5 Billion of Senior Notes
4. Addressing the Pharmacist Shortage: Medco Labor Coalition(TM) Launches National Scholarship Program to Support the Development of the Next Generation of Pharmacists
5. Medco Chooses AllPoints at Anson in Whitestown, Indiana as Site for the Worlds Largest, Most-Advanced Automated Pharmacy
6. Medco to Webcast Annual Analyst Day Conference
7. Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion
8. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
9. Fat droplet nanoparticle delivers tumor suppressor gene to tumor and metastatic cells
10. Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion
11. ICON Delivers New Electronic Solution to Expedite Clinical Trial Adjudication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)...  EMD Serono today announced the US biopharmaceutical ... , appointed Alise Reicin , MD, ... Development.  Dr. Reicin brings extensive research and early/late ... Immunology. She is an accomplished pharmaceutical executive with ... President in various capacities across R&D at MSD ...
(Date:4/16/2015)... and MENLO PARK, Calif. , April ... DMPI) (DelMar and the Company), a biopharmaceutical company focused ... orphan drug indications, today announced that the Mayo ... clinical trial site for the ongoing, multicenter Phase I/II ... (GBM), the most common and deadly form of human ...
(Date:4/16/2015)... 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ... DCVax® personalized immune therapies for cancer, announced today ... Cancer Immunotherapy Index (LCINDX), a professional index recently ... field within the biotechnology space.  ... companies" in the immunotherapy space, including 6 big ...
(Date:4/16/2015)... Tex. (PRWEB) April 16, 2015 ... chain management systems for highly regulated industries, is ... been name a monthly columnist for Cold Chain ... ( http://www.coldchainiq.com ). His column titled, Global Cold ... chain information for today’s life sciences, pharmaceutical and ...
Breaking Biology Technology:Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 2NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 3Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 2Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 3
... April 12, 2011 Reportlinker.com announces that a new ... Biomarker Partnering Terms and Agreements ... The Biomarker Partnering Terms and Agreements report ... partnering deals and agreements entered into by the worlds ...
... April 11, 2011 Shrink Nanotechnologies, Inc. ("Shrink") (OTC ... that it has executed a binding letter of intent ... biomedical instrumentation and microfluidics company with global distribution for ... The transaction highlights are: Shrink ...
... Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), ... development, manufacture and sale of enzyme and protein ... industries, today announced that its President and Chief ... Advanced Biofuels Leadership Conference taking place from April ...
Cached Biology Technology:Reportlinker Adds Biomarker Partnering Terms and Agreements 2Reportlinker Adds Biomarker Partnering Terms and Agreements 3Reportlinker Adds Biomarker Partnering Terms and Agreements 4Reportlinker Adds Biomarker Partnering Terms and Agreements 5Reportlinker Adds Biomarker Partnering Terms and Agreements 6Reportlinker Adds Biomarker Partnering Terms and Agreements 7Reportlinker Adds Biomarker Partnering Terms and Agreements 8Shrink Nanotechnologies Signs Binding Letter of Intent to Acquire 100% of Hawaii-Based Nanopoint, Inc. 2Shrink Nanotechnologies Signs Binding Letter of Intent to Acquire 100% of Hawaii-Based Nanopoint, Inc. 3Shrink Nanotechnologies Signs Binding Letter of Intent to Acquire 100% of Hawaii-Based Nanopoint, Inc. 4Dyadic International to Present at Advanced Biofuels Leadership Conference 2
(Date:3/23/2015)... OXFORD, Conn. , Mar. 23, 2015 NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market, announces ... a new advertising campaign on CNBC television starting March 30 ... ads will commence airing in New York ... Executive Officer said: "We are excited about our new ad ...
(Date:3/20/2015)... 19, 2015 Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ... - Global Strategic Business Report" report to their offering. ... Biometrics in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ... Latin America . Annual estimates ...
(Date:3/17/2015)... 17, 2015 Emotient, the leader in ... announced general availability of Emotient Analytics , ... analysis of facial expressions. The system analyzes videos ... products and services. It delivers audience response metrics ... - as derived from facial evidence of emotional ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... discovery made by researchers at the Institut de recherches ... Di Noia, Director of the Mechanisms and Genetic Diversity ... Journal of Experimental Medicine . The team identified a ... for the therapy of some types of lymphoma and ...
... State University are developing a cost-effective electronic monitoring system ... critical coastal ecosystems by allowing users to track water-quality ... support from a National Science Foundation (NSF) grant. ... to monitor environmental conditions in the Chesapeake Bay, the ...
... London, UK (November 1, 2010) In April 2010, ... on the conclusion that the current missile defense systems will ... of nuclear-armed combat. Now research in the Bulletin of ... have not been tested against real-world threats and would not ...
Cached Biology News:A discovery could be important for the therapy of lymphoma and leukemia 2Researchers developing real-time electronic monitoring for coastal waters 2US nuclear safety claim is a 'dangerous fantasy' 2US nuclear safety claim is a 'dangerous fantasy' 3